{
    "ticker": "SRBK",
    "name": "Sarepta Therapeutics, Inc.",
    "description": "Sarepta Therapeutics, Inc. is a leading biotechnology company focused on the development of precision genetic medicine to treat rare diseases, with a primary emphasis on Duchenne muscular dystrophy (DMD). Founded in 1980 and headquartered in Cambridge, Massachusetts, Sarepta has pioneered the use of RNA-targeted therapeutics and gene therapy, which enable the body to produce functional dystrophin, a protein essential for muscle health. The company\u2019s lead product candidate, Eteplirsen, is designed to treat individuals with DMD who have specific genetic mutations. Sarepta's innovative approach has garnered attention in the scientific community and among patients and families affected by DMD, as it represents a potential breakthrough in treatment options. In addition to Eteplirsen, Sarepta has a robust pipeline of product candidates, including treatments in various stages of clinical trials for other rare diseases. The company is committed to advancing its therapies through rigorous research and development, with a vision to transform the lives of patients living with serious genetic disorders. Sarepta's mission extends beyond drug development; it actively engages with the patient community, advocates for policies that support rare disease research, and collaborates with healthcare professionals and academic institutions to enhance the understanding and treatment of genetic disorders.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "1980",
    "website": "https://www.sareptatherapeutics.com",
    "ceo": "Doug Ingram",
    "social_media": {
        "twitter": "https://twitter.com/Sarepta",
        "linkedin": "https://www.linkedin.com/company/sareptatherapeutics/"
    },
    "investor_relations": "https://investors.sareptatherapeutics.com",
    "key_executives": [
        {
            "name": "Doug Ingram",
            "position": "CEO"
        },
        {
            "name": "Sharon H. Hrynkow",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Duchenne Muscular Dystrophy Treatments",
            "products": [
                "Eteplirsen",
                "Golodirsen",
                "Viltolarsen"
            ]
        },
        {
            "category": "Gene Therapy",
            "products": [
                "Gene Therapy Programs"
            ]
        }
    ],
    "seo": {
        "meta_title": "Sarepta Therapeutics, Inc. | Precision Genetic Medicine for Rare Diseases",
        "meta_description": "Explore Sarepta Therapeutics, Inc., a leader in biotechnology focused on precision genetic medicine and innovative treatments for rare diseases like Duchenne muscular dystrophy.",
        "keywords": [
            "Sarepta",
            "Duchenne Muscular Dystrophy",
            "Biotechnology",
            "Gene Therapy",
            "Eteplirsen"
        ]
    },
    "faq": [
        {
            "question": "What is Sarepta Therapeutics known for?",
            "answer": "Sarepta Therapeutics is known for its development of precision genetic medicine, particularly for treating Duchenne muscular dystrophy."
        },
        {
            "question": "Who is the CEO of Sarepta Therapeutics?",
            "answer": "Doug Ingram is the CEO of Sarepta Therapeutics, Inc."
        },
        {
            "question": "Where is Sarepta Therapeutics headquartered?",
            "answer": "Sarepta Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are Sarepta's main products?",
            "answer": "Sarepta's main products include Eteplirsen, Golodirsen, and Viltolarsen for the treatment of Duchenne muscular dystrophy."
        },
        {
            "question": "When was Sarepta Therapeutics founded?",
            "answer": "Sarepta Therapeutics was founded in 1980."
        }
    ],
    "competitors": [
        "PTCT",
        "BMRN",
        "SGMO"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX"
    ]
}